TTrialPathMatch Me to Trials
← Back to trials
RecruitingParkinson DiseaseMild Cognitive Impairment

Superior Parietal iTBS for PD-MCI

Eligible age

50–85 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this study is to determine the whether a short-term, high-dose form of non-invasive brain stimulation (intermittent theta burst stimulation; iTBS) is a promising and safe treatment for mild cognitive impairment in Parkinson's disease (PD-MCI).

Sponsor: Medical University of South Carolina

You may qualify if…

  • ✓ 50-85 years of age
  • ✓ Diagnosis of Parkinson's disease based on UK Brain Bank diagnostic criteria
  • ✓ Parkinson's disease with mild cognitive impairment (PD-MCI) diagnosis per Movement Disorders Society Task Force Level II Diagnostic Criteria4 (i.e., scores ≥1.5 standard deviations below appropriate norms on 2 neuropsychological tests) as determined by a clinical neuropsychologist
  • ✓ Stable on Parkinson's disease medications for 30 days (not expected to change through the course of the treatment)
  • ✓ Has a caregiver willing and able to reliably complete a questionnaire focused on the participant's daily functioning

You may not qualify if…

  • ✕ Claustrophobia or inability to lie supine in the scanner for an extended period of time
  • ✕ Barriers to making contact between the TMS coil and the skin (e.g. braids that cannot be removed)
  • ✕ Contraindications to MRI/TMS safety screening: This includes but is not limited to implanted medical devices (e.g., pacemakers), metallic objects or fragments, non-removable hair clips or piercings, and medications that reduce seizure threshold.
  • ✕ Individuals with a diagnosis of bipolar disorder, schizophrenia, and/or active substance abuse disorder.
  • ✕ History of significant or unstable condition/s or treatments for these condition/s that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. multiple sclerosis, moderate to severe brain injury, seizures).
  • ✕ History of a seizure disorder.

Where it's recruiting

South Carolina

Charleston

Source: ClinicalTrials.gov · NCT07701785 · last updated 2026-07-14

Superior Parietal iTBS for PD-MCI · TrialPath